Specgx llc Pharmaceuticals is a subsidiary of Mallinckrodt plc that operates its Specialty Generics business. The company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application in accordance with investigational abuse-deterrent, immediate-release reformulation of Roxicodone tablets, USP for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The trusted manufacturer has a strong ability to master and manage the complexity of its products. It provides high-quality products that mean value for people suffering from a particular health condition. The leading company has a growing portfolio of specialty medicines that treats a wide variety of health conditions. Specgx llc Pharmaceuticals visions for an innovation-driven specialty pharmaceutical company focused on improving people’s life.

The growing company has invested in the areas that include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products.

For more than 150 years, Specgx llc Pharmaceuticals has remained focused on producing quality products with integrity and unparalleled service to serve the people across the globe. It provides medical solutions for communities living in remote areas.